Investigates the impact of beta-glucan and inactivated parapoxvirus ovis on serum OAS1 levels in distemper-infected dogs, suggesting treatment implications.
Oligoadenylate synthase proteins are activated through interaction with viral double-stranded RNA, where they polymerise ATP into 2',5'-linked oligoadenylates that subsequently bind and activate latent ribonuclease L. Once activated, ribonuclease L degrades both viral and cellular RNA, ultimately resulting in the suppression of protein synthesis. The present study was designed to investigate the impact of beta-glucan and inactivated parapoxvirus ovis strain D1701, used alongside standard therapy, on serum 2',5'-oligoadenylate synthetase 1 (OAS1) activity. The study included 60 unvaccinated dogs, that displayed respiratory and gastrointestinal symptoms of distemper and were confirmed positive using a rapid diagnostic test. Dogs were randomly divided into three groups. Group I received only standard treatment, Group II was given beta-glucan 1.3/1.6 in addition to standard treatment, and Group III received inactivated parapoxvirus ovis strain D1701 alongside standard therapy. After treatment, OAS1 levels increased by 74.4% in Group I, 8.96% in Group II, and 142.45% in Group III compared to pre-treatment levels. These results suggest that serum OAS1 levels increased in treated dogs with distemper, with the increase being lowest in the beta-glucan group. However, additional studies directly correlating serum OAS1 levels with disease severity or prognosis are needed.
No takes yet. Share an insight, caveat, or question.
Rıhtım et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: